angiotensin
convert
enzym
endogen
regul
renin
angiotensin
system
increas
circul
predict
advers
outcom
patient
heart
failur
hf
unknown
elev
plasma
activ
predict
major
advers
cardiovascular
event
mace
patient
obstruct
coronari
arteri
diseas
cad
prospect
recruit
patient
obstruct
cad
defin
stenosi
left
main
coronari
arteri
andor
stenosi
major
epicardi
vessel
invas
coronari
angiographi
measur
plasma
activ
patient
follow
determin
circul
activ
level
predict
primari
endpoint
mace
cardiovascular
mortal
hf
myocardi
infarct
recruit
patient
obstruct
coronari
arteri
diseas
median
iqr
plasma
activ
pmolmlmin
median
follow
year
mace
occur
patient
event
kaplanmei
analysi
abovemedian
plasma
activ
associ
mace
logrank
test
p
hf
hospitalis
p
cox
multivari
adjust
log
activ
remain
independ
predictor
mace
hazard
ratio
hr
confid
interv
ci
p
hf
hospitalis
hr
ci
p
introduct
cardiovascular
cv
diseas
major
caus
morbid
mortal
associ
activ
reninangiotensin
system
ra
within
ra
angiotensin
convert
enzym
ace
convert
angiotensin
ang
vasoconstrictor
proatherosclerot
peptid
ang
ii
whilst
endogen
inhibitor
ra
major
action
degrad
ang
ii
highli
express
heart
blood
vessel
cleav
cell
surfac
releas
catalyt
activ
ectodomain
circul
action
tumour
necrosi
factor
alpha
convert
enzym
tace
human
myocardium
local
endothelium
microcircul
also
present
media
atherosclerot
radial
arteri
healthi
individu
circul
activ
level
low
increas
presenc
cv
diseas
risk
factor
includ
heart
failur
hf
atrial
fibril
af
kidney
diseas
type
diabet
date
limit
inform
prognost
role
circul
activ
level
result
conflict
exampl
increas
activ
predict
advers
cv
outcom
heart
failur
patient
emerg
orthoped
surgeri
chronic
kidney
diseas
differ
may
reflect
patient
popul
rel
cardiovascular
risk
patient
popul
length
follow
aim
studi
investig
util
plasma
activ
level
predict
cv
event
highrisk
cohort
patient
angiograph
proven
obstruct
cad
year
followup
consecut
patient
age
year
prospect
recruit
novemb
januari
referr
tertiari
cardiovascular
centr
coronari
angiogram
investig
suspect
cad
signific
obstruct
cad
elig
studi
patient
cardiogen
shock
past
histori
congest
heart
failur
left
ventricular
lv
eject
fraction
angiographi
exclud
ethic
approv
obtain
human
research
ethic
committe
austin
health
melbourn
studi
compli
declar
helsinki
patient
gave
inform
written
consent
standardis
medic
questionnair
complet
verifi
hospit
medic
record
blood
pressur
measur
anthropometr
measur
taken
obstruct
cad
defin
stenosi
left
main
coronari
arteri
andor
stenosi
major
epicardi
coronari
arteri
visual
assess
invas
coronari
angiographi
diabet
diagnos
base
document
histori
treatment
glucos
lower
therapi
fast
blood
glucos
mmoll
hypertens
defin
previous
diagnos
physician
andor
current
use
antihypertens
medic
dyslipidaemia
defin
previous
diagnos
physician
andor
current
use
lipid
lower
agent
cigarett
smoke
defin
smoke
within
preced
month
fast
blood
sampl
collect
time
admiss
measur
kidney
function
lipid
troponin
access
accutni
assay
beckmancoult
chaska
mn
usa
use
measur
plasma
troponin
th
percentil
healthi
refer
popul
level
th
percentil
consid
abnorm
studi
plasma
measur
blood
collect
within
hour
present
lithium
heparin
tube
plasma
obtain
centrifug
blood
rpm
minut
store
test
plasma
activ
measur
within
year
sampl
collect
sampl
batch
assay
run
period
day
catalyt
activ
measur
use
valid
sensit
quench
fluoresc
substratebas
assay
previous
describ
briefli
plasma
ml
dilut
lowionicstrength
buffer
mmoll
trishcl
ph
ad
anxsepharos
fastflow
resin
amersham
bioscienc
ge
healthcar
uppsala
sweden
remov
previous
character
endogen
inhibitor
activ
bind
wash
result
eluat
assay
catalyt
activ
duplic
sampl
incub
quench
fluoresc
substrat
without
mm
ethylenediaminetetraacet
acid
rate
substrat
cleavag
determin
comparison
standard
curv
free
fluorophor
mca
sigma
mo
usa
express
substrat
cleavedml
plasmamin
intraassay
interassay
coeffici
variat
respect
primari
endpoint
composit
major
advers
cardiac
event
mace
defin
cv
death
hospitalis
hf
myocardi
infarct
mi
secondari
endpoint
hf
hospitalis
endpoint
describ
accord
american
colleg
cardiolog
american
heart
associ
definit
cv
endpoint
clinic
trial
cv
death
defin
death
due
sudden
cardiac
death
hf
acut
mi
cerebrovascular
accid
cv
haemorrhag
cv
procedur
cv
caus
death
includ
previou
categori
specif
known
cv
caus
pulmonari
embol
hospitalis
hf
defin
event
patient
admit
hospit
primari
diagnosi
hf
length
stay
least
hour
patient
exhibit
new
worsen
symptom
heart
failur
present
object
evid
new
worsen
heart
failur
receiv
intensif
treatment
specif
heart
failur
myocardi
infarct
defin
clinic
diagnosi
st
elev
nonst
elev
myocardi
infarct
accord
establish
criteria
clinic
outcom
collect
experienc
blind
investig
via
medic
record
review
contact
patient
andor
nomin
gener
practition
addit
inform
statist
analysi
perform
use
stata
version
statacorp
colleg
station
tx
usa
normal
distribut
continu
variabl
express
mean
standard
deviat
nonnorm
distribut
data
plasma
activ
triglycerid
troponin
glomerular
filtrat
rate
express
median
interquartil
rang
iqr
student
test
mann
whitney
u
test
nonnorm
distribut
data
use
assess
differ
continu
variabl
patient
median
activ
categor
variabl
express
count
percentag
compar
use
fisher
exact
chisquar
test
multipl
regress
analysi
use
identifi
variabl
may
independ
influenc
plasma
activ
plasma
activ
troponin
level
glomerular
filtrat
rate
naturallogarithm
transform
analysi
skew
distribut
render
normal
distribut
visual
inspect
distribut
variabl
qq
plot
cumul
incid
mace
estim
kaplan
meier
method
logrank
test
use
evalu
differ
patient
median
plasma
activ
multipl
endpoint
occur
followup
time
first
event
consid
analysi
mace
cox
proport
hazard
model
use
estim
adjust
hazard
ratio
hr
confid
interv
ci
mace
signific
variabl
p
univari
analysi
enter
final
multivari
model
identifi
independ
predictor
mace
convent
prognost
variabl
use
includ
age
histori
diabet
log
troponin
treatment
statin
betablock
ace
inhibitor
angiotensin
receptor
blocker
addit
log
twotail
pvalu
consid
signific
recruit
patient
angiograph
proven
obstruct
cad
patient
lost
follow
median
followup
year
iqr
year
clinic
biochem
characterist
studi
popul
present
tabl
cohort
compris
male
mean
sd
age
year
bmi
kgm
patient
signific
cv
risk
smoke
histori
histori
cad
dyslipidaemia
hypertens
diabet
af
regard
pharmacolog
therapi
time
present
angiotensin
convert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
betablock
statin
aspirin
patient
categor
accord
plasma
activ
median
level
patient
abovemedian
plasma
activ
like
male
af
tabl
p
multipl
regress
analysi
perform
identifi
variabl
influenc
plasma
activ
male
gender
independ
predictor
higher
activ
p
preval
cad
cardiac
risk
factor
includ
dyslipidaemia
hypertens
diabet
cigarett
smoke
similar
two
group
lvef
use
pharmacolog
agent
low
densiti
lipoprotein
cholesterol
triglycerid
level
kidney
function
troponin
level
p
followup
period
death
myocardi
infarct
hospitalis
hf
primari
endpoint
mace
composit
cv
mortal
hf
hospitalis
mi
occur
patient
median
level
pmolmlmin
significantli
associ
higher
incid
mace
logrank
test
p
fig
hf
hospitalis
p
fig
compar
belowmedian
signific
differ
incid
cv
death
p
mi
p
subgroup
analysi
includ
male
patient
signific
differ
incid
mace
accord
median
level
p
surviv
analysi
use
cox
regress
model
indic
age
histori
atrial
fibril
histori
diabet
log
univari
predictor
primari
endpoint
mace
multivari
cox
regress
analysi
log
activ
remain
signific
predictor
mace
hr
ci
p
tabl
regard
secondari
endpoint
hf
log
hr
ci
p
age
hr
ci
p
independ
predictor
heart
failur
major
find
current
studi
plasma
activ
independ
increas
hazard
advers
cardiovascular
event
patient
signific
obstruct
cad
studi
highrisk
patient
follow
median
year
elev
activ
remain
independ
predictor
cv
mortal
morbid
even
comprehens
multivari
adjust
model
includ
prognost
meaning
variabl
median
level
patient
cad
pmolmlmin
higher
level
previous
report
young
healthi
volunt
pmolmlmin
elderli
patient
median
pmolmlmin
exclud
patient
known
hf
sever
lv
systol
dysfunct
associ
increas
circul
level
consist
result
studi
plasma
activ
higher
male
patient
found
independ
predictor
plasma
activ
level
conflict
find
regard
prognost
valu
circul
level
like
reflect
differ
followup
period
risk
cv
event
across
studi
popul
cohort
patient
hf
n
advers
cv
event
death
cardiac
transplant
hf
hospitalis
month
follow
circul
level
remain
independ
predictor
adjust
reduc
eject
fraction
increas
nterminalpro
brain
natriuret
peptid
anoth
cohort
patient
chronic
kidney
diseas
ckd
without
prior
cv
diseas
circul
activ
independ
predictor
cv
mortal
event
followup
period
month
concord
group
report
signific
associ
elev
circul
activ
advers
cv
outcom
patient
ckd
stage
iii
iv
haemodialysi
patient
kidney
transplant
recipi
also
found
elderli
patient
undergo
emerg
orthopaed
surgeri
elev
level
predict
cv
event
month
followup
p
ascrib
signific
associ
increas
plasma
activ
advers
cv
outcom
seen
present
studi
higher
rate
cv
outcom
observ
studi
cohort
longer
followup
durat
sever
line
evid
suggest
plasma
activ
may
serv
marker
atherosclerosi
nondialysi
patient
ckd
circul
activ
associ
silent
atherosclerosi
carotid
peripher
vessel
patient
type
diabet
histori
cad
circul
activ
increas
pattern
observ
kidney
transplant
recipi
histori
cad
support
associ
rais
circul
activ
coronari
atherosclerosi
anoth
studi
patient
angiograph
confirm
cad
ortizperez
et
al
demonstr
elev
level
circul
baselin
patient
present
stelev
myocardi
infarct
compar
control
group
patient
without
known
cad
therefor
clear
ortizperez
et
al
studi
whether
increas
circul
reflect
acut
cardiac
injuri
underli
atherosclerosi
studi
extend
knowledg
regard
includ
patient
angiograph
proven
obstruct
coronari
arteri
diseas
without
acut
present
differ
accord
present
result
suggest
increas
plasma
reflect
underli
atherosclerosi
rather
acut
myocardi
injuri
import
ra
pathogenesi
atherosclerosi
well
establish
inde
target
pharmacolog
inhibit
classic
ra
improv
outcom
atherosclerot
diseas
includ
cad
experiment
model
atherosclerosi
other
report
express
vascular
endotheli
cell
macrophag
smooth
muscl
cell
within
atherosclerot
plaqu
also
report
present
atherosclerot
blood
vessel
patient
cad
undergo
coronari
arteri
bypass
surgeri
experiment
studi
shown
overexpress
promot
atherosclerot
plaqu
stabil
attenu
atherosclerot
lesion
activ
tace
result
increas
shed
tissu
circul
shed
henc
loss
tissu
mediat
angiotensin
ii
result
proinflammatori
effect
angiotensin
ii
unoppos
certainli
rabbit
model
atherosclerosi
gene
silenc
tace
enhanc
plaqu
stabil
improv
vascular
remodel
possibl
via
reduc
tissu
shed
find
reinforc
import
counterregulatori
role
atherosclerosi
suggest
modul
could
offer
futur
therapeut
option
patient
atherosclerot
diseas
relationship
tissu
circul
level
yet
understood
postul
plasma
level
may
parallel
tissu
express
constant
rate
shed
normal
physiolog
although
studi
concurr
measur
tissu
circul
tace
level
address
hypothesi
find
rais
possibl
human
atherosclerosi
increas
plasma
activ
advers
cardiovascular
outcom
reflect
persist
albeit
insuffici
counterregulatori
process
shift
balanc
away
deleteri
effect
sustain
ang
ii
activ
genet
variat
around
gene
encod
may
account
differ
express
activ
inde
locat
gene
within
x
chromosom
area
gene
known
escap
xinactiv
may
contribut
phenotyp
differ
sex
tissuespecif
differ
xinactiv
furthermor
polymorph
gene
associ
poorer
outcom
two
separ
cad
cohort
chines
han
european
ancestri
yet
studi
combin
genet
approach
measur
plasma
activ
studi
number
limit
includ
rel
small
sampl
size
use
convent
troponin
assay
high
sensit
assay
avail
time
patient
recruit
furthermor
find
elev
plasma
activ
associ
advers
outcom
suggest
possibl
relationship
determin
caus
effect
howev
major
strength
includ
detail
angiograph
assess
long
term
follow
conclus
studi
demonstr
elev
plasma
activ
independ
predictor
mace
patient
obstruct
cad
studi
identifi
potenti
surrog
marker
cv
outcom
possibl
target
therapeut
intervent
whether
target
patient
increas
plasma
level
intens
therapi
would
lead
improv
outcom
yet
test
